Tianjin expert consensus on the prevention and treatment of refractory chemotherapy-related nausea and vomiting (2025 edition)

doi:10.11958/20240783

Abstract

Abstract:

Nausea and vomiting are the most common adverse reactions of chemotherapy. In recent years, with the progression of palliative and supportive care, the prevention and control rate of chemotherapy induced nausea and vomiting (CINV) have been effectively improved. However, a small number of CINV still cannot be controlled satisfactorily or recurrence after receiving CINV prevention and treatments, which gradually develops into refractory CINV. Refractory CINV is a very difficult problem in the field of supportive care, which seriously affects the quality of life of patients, chemotherapy progress and prognosis. Therefore, Tianjin Anti-Cancer Association Committee of Rehabilitation and Palliative Care and Tianjin Medical Doctor Association Committee of Tumor Multidisciplinary Diagnosis and Treatment (MDT) organized experts to formulate a Tianjin expert consensus on the prevention and treatment of refractory CINV. The concept of refractory CINV, prevention and treatment strategies, specific medication guidance, traditional Chinese medical treatments, nursing and MDT management are summarized. Meanwhile, the corresponding recommendations are also given in order to provide more reference for improving the prevention and treatment of refractory CINV. This consensus only provides academic guidance for refractory CINV, the specific implementation plans need to be determined based on actual clinical conditions.

Key words: nausea, vomiting, refractory nausea and vomiting, chemotherapy induced nausea and vomiting, prevention and treatment, consensus

CLC Number:

R453，R730.5

Figures/Tables 1

References 38

[1]	陈薇, 方赛男, 刘建平, 等. 国际循证医学证据分级体系的发展与现状[J]. 中国中西医结合杂志, 2017, 37(12):1413-1419.
	CHEN W, FANG S N, LIU J P, et al. Development and current status of the international evidence-based medicine evidence grading system[J]. Chinese Journal of Integrative Medicine and Western Medicine, 2017, 37(12):1413-1419. doi:10.7661/j.cjim.20171114.26.
[2]	NAVARI R M. Management of chemotherapy-induced nausea and vomiting:focus on newer agents and new uses for older agents[J]. Drugs, 2013, 73(3):249-262. doi:10.1007/s40265-013-0019-1.
[3]	MARTIN A R, PEARSON J D, CAI B, et al. Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives:a modified version of the Functional Living Index-Emesis(FLIE) with 5-day recall [J]. Support Care Cancer, 2003, 11(8):522-527. doi:10.1007/s00520-003-0482-4.
[4]	张玉. 化疗所致恶心呕吐的药物防治指南[J]. 中国医院药学杂志, 2022, 42(5): 457-473.
	ZHANG Y. Guidelines for pharmacological control of chemotherapy-induced nausea and vomiting[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(5): 457-473. doi:10.13286/j.1001-5213.2022.05.01.
[5]	ZIGMOND A S, SNAITH R P. The hospital anxiety and depression scale[J]. Acta Psychiatr Scand, 1983, 67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.
[6]	AAPRO M. CINV:still troubling patients after all these years[J]. Support Care Cancer, 2018, 26(Suppl 1):5-9. doi:10.1007/s00520-018-4131-3.
[7]	AAPRO M, MOLASSIOTIS A, DICATO M, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV):the Pan European Emesis Registry(PEER)[J]. Ann Oncol, 2012, 23(8):1986-1992. doi:10.1093/annonc/mds021.
[8]	NAVARI R M. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting[J]. Biomed Res Int, 2015,2015:595894. doi:10.1155/2015/595894.
[9]	MUKHOPADHYAY S, DUTTA P, BANERJEE S, et al. Low-dose olanzapine,sedation and chemotherapy-induced nausea and vomiting:a prospective randomized controlled study[J]. Future Oncol, 2021, 17(16):2041-2056. doi:10.2217/fon-2020-0834.
[10]	HATA A, KATAKAMI N, FUJITA S, et al. Medroxyprogesterone acetate for refractory emesis in cisplatin-treated patients[J]. J Palliat Med, 2012, 15(10):1158-1160. doi:10.1089/jpm.2011.0527.
[11]	RAFTOPOULOS H, COOPER W, O'BOYLE E, et al. Comparison of an extended-release formulation of granisetron(APF530)versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy:results of a prospective,randomized,double-blind,noninferiority phase 3 trial[J]. Support Care Cancer, 2015, 23(3):723-732. doi:10.1007/s00520-014-2400-3.
[12]	LOPRINZI C L, MICHALAK J C, SCHAID D J, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia[J]. J Clin Oncol, 1993, 11(4):762-767. doi:10.1200/JCO.1993.11.4.762.
[13]	MILLER S, MCNUTT L, MCCANN M A, et al. Use of corticosteroids for anorexia in palliative medicine:a systematic review[J]. J Palliat Med, 2014, 17(4):482-485. doi:10.1089/jpm.2013.0324.
[14]	NAITO T, UCHINO J, KOJIMA T, et al. A multicenter,open-label,single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index[J]. Cancer, 2022, 128(10):2025-2035. doi:10.1089/jpm.2013.0324.
[15]	MOSA A S M, HOSSAIN A M, LAVOIE B J, et al. Patient-related risk factors for chemotherapy-induced nausea and vomiting:a systematic review[J]. Front Pharmacol, 2020,11:329. doi:10.3389/fphar.2020.00329.
[16]	RAZAVI D, DELVAUX N, FARVACQUES C, et al. Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy:a double-blind,placebo-controlled study assessing the usefulness of alprazolam[J]. J Clin Oncol, 1993, 11(7):1384-1390. doi:10.1200/JCO.1993.11.7.1384.
[17]	JAMES A, NAIR M M, ABRAHAM D S, et al. Effect of lorazepam in reducing psychological distress and anticipatory nausea and vomiting in patients undergoing chemotherapy[J]. J Pharmacol Pharmacother, 2017, 8(3):112-115. doi:10.4103/jpp.JPP_54_17.
[18]	LIM B, SPROULE B A, ZAHRA Z, et al. Understanding the effects of chronic benzodiazepine use in depression:a focus on neuropharmacology[J]. Int Clin Psychopharmacol, 2020, 35(5):243-253. doi:10.1097/YIC.0000000000000316.
[19]	CHAN A, KIM H K, HSIEH R K, et al. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis[J]. Support Care Cancer, 2015, 23(1):283-291. doi:10.1007/s00520-014-2375-0.
[20]	REDD W H, MONTGOMERY G H, DUHAMEL K N. Behavioral intervention for cancer treatment side effects[J]. J Natl Cancer Inst, 2001, 93(11):810-823. doi:10.1093/jnci/93.11.810.
[21]	HUNTER J J, MAUNDER R G, SUI D, et al. A randomized trial of nurse-administered behavioral interventions to manage anticipatory nausea and vomiting in chemotherapy[J]. Cancer Med, 2020, 9(5):1733-1740. doi:10.1002/cam4.2863.
[22]	GAO A, GUAN S, SUN Y, et al. Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV)in patients receiving highly emetogenic chemotherapy[J]. BMC Cancer, 2023, 23(1):609. doi:10.1186/s12885-023-11070-3.
[23]	OLVER I N, GRIMISON P, CHATFIELD M, et al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy[J]. Support Care Cancer, 2013, 21(6):1561-1568. doi:10.1007/s00520-012-1696-0.
[24]	KAPOOR A, JAIN A, SHARMA A, et al. Chemotherapy-induced nausea and vomiting in gastrointestinal cancer patients:do we need to revisit guidelines?[J]. South Asian J Cancer, 2020, 9(4):245-249. doi:10.1055/s-0041-1729493.
[25]	TAKESHIMA N, MATODA M, ABE M, et al. Efficacy and safety of triple therapy with aprepitant,palonosetron,and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer:KCOG-G1003 phase II trial[J]. Support Care Cancer, 2014, 22(11):2891-2898. doi:10.1007/s00520-014-2280-6.
[26]	MARBURY T C, NGO P L, SHADLE C R, et al. Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjects[J]. J Clin Pharmacol, 2011, 51(12):1712-1720. doi:10.1177/0091270010387792.
[27]	FIGG W D, DUKES G E, PRITCHARD J F, et al. Pharmacokinetics of ondansetron in patients with hepatic insufficiency[J]. J Clin Pharmacol, 1996, 36(3):206-215. doi:10.1002/j.1552-4604.1996.tb04190.x.
[28]	ZHANG J, CUI X, YANG C, et al. A deep learning-based interpretable decision tool for predicting high risk of chemotherapy-induced nausea and vomiting in cancer patients prescribed highly emetogenic chemotherapy[J]. Cancer Med, 2023, 12(17):18306-18316. doi:10.1002/cam4.6428.
[29]	BAEK J Y, TRINH T A, HUH W, et al. Electro-acupuncture alleviates cisplatin-induced anorexia in rats by modulating ghrelin and monoamine neurotransmitters[J]. Biomolecules, 2019, 9(10):624. doi:10.3390/biom9100624.
[30]	KONG F, WANG Z, WANG N, et al. The clinical observation of acupuncture combined with antiemetic drugs in the prevention and treatment of CINV in breast cancer patients[J]. Front Oncol, 2022,12:888651. doi:10.3389/fonc.2022.888651.
[31]	李宛璎, 李柳宁. 艾炷灸防治肺癌顺铂化疗所致恶心呕吐疗效观察[J]. 中国针灸, 2018, 38(7):695-699.
	LI W Y, LI L N. Observation on the efficacy of moxa cone moxibustion in the prevention and treatment of nausea and vomiting caused by cisplatin chemotherapy for lung cancer[J]. Chinese Acupuncture and Moxibustion, 2018, 38(7):695-699. doi:10.13703/j.0255-2930.2018.07.003.
[32]	RAJABALIZADEH R, GHASEMZADEH RAHBARDAR M, HOSSEINZADEH H. Medicinal herbs in treating chemotherapy-induced nausea and vomiting:a review[J]. Phytother Res, 2022, 36(10):3691-3708. doi:10.1002/ptr.7563.
[33]	刘苗苗, 时光喜, 宋立, 等. 中药减轻乳腺癌术后化疗相关恶心呕吐的Meta分析[J]. 山东中医杂志, 2021, 40(10):1086-1094.
	LIU M M, SHI G X, SONG L, et al. Meta-analysis of Chinese medicine to reduce nausea and vomiting associated with postoperative chemotherapy for breast cancer[J]. Shandong Journal of Traditional Chinese Medicine, 2021, 40(10):1086-1094. doi:10.16295/j.cnki.0257-358x.2021.10.011.
[34]	BREARLEY S G, CLEMENTS C V, MOLASSIOTIS A. A review of patient self-report tools for chemotherapy-induced nausea and vomiting[J]. Support Care Cancer, 2008, 16(11):1213-1229. doi:10.1007/s00520-008-0428-y.
[35]	GUPTA K, WALTON R, KATARIA S P. Chemotherapy-induced nausea and vomiting:pathogenesis,recommendations,and new trends[J]. Cancer Treat Res Commun, 2021,26:100278. doi:10.1016/j.ctarc.2020.100278.
[36]	TIAN X, TANG R Y, XU L L, et al. Progressive muscle relaxation is effective in preventing and alleviating of chemotherapy-induced nausea and vomiting among cancer patients:a systematic review of six randomized controlled trials[J]. Support Care Cancer, 2020, 28(9):4051-4058. doi:10.1007/s00520-020-05481-2.
[37]	WEI T T, TIAN X, ZHANG F Y, et al. Music interventions for chemotherapy-induced nausea and vomiting:a systematic review and meta-analysis[J]. Support Care Cancer, 2020, 28(9):4031-4041. doi:10.1007/s00520-020-05409-w.
[38]	李晓莉, 孟爱凤, 徐桂华, 等. 癌症患者居家口服化疗用药安全管理的研究进展[J]. 护理学杂志, 2021, 36(8):25-28.
	LI X L, MENG A F, XU G H, et al. Research progress on the safe management of oral chemotherapy medication in cancer patients at home[J]. Journal of Nursing, 2021, 36(8):25-28. doi:10.3870/j.issn.1001-4152.2021.08.025.

项目名称	证据等级	描述	研究类型
证据分级	高级证据	非常确信真实的效应值接近效应估计	随机对照试验（RCT）；质量升高2级的观察性研究
	中级证据	对效应估计值有中等程度的信心：真实值有可能接近估计值，但仍存在二者大不相同的可能性	质量降低1级的RCT；质量升高1级的观察性研究
	低级证据	对效应估计值的确信程度有限：真实值可能与估计值大不相同	质量降低2级的RCT；观察性研究
	极低级证据	对效应估计值几乎没有信心：真实值很可能与估计值大不相同	质量降低3级的RCT；质量降低1级的观察性研究；系列病例观察；个案报道
推荐强度	强	明确显示干预措施利大于弊或弊大于利
推荐强度	弱	利弊不确定或无论质量高低的证据均显示利弊相当

项目名称	证据等级	描述	研究类型
证据分级	高级证据	非常确信真实的效应值接近效应估计	随机对照试验（RCT）；质量升高2级的观察性研究
	中级证据	对效应估计值有中等程度的信心：真实值有可能接近估计值，但仍存在二者大不相同的可能性	质量降低1级的RCT；质量升高1级的观察性研究
	低级证据	对效应估计值的确信程度有限：真实值可能与估计值大不相同	质量降低2级的RCT；观察性研究
	极低级证据	对效应估计值几乎没有信心：真实值很可能与估计值大不相同	质量降低3级的RCT；质量降低1级的观察性研究；系列病例观察；个案报道
推荐强度	强	明确显示干预措施利大于弊或弊大于利
推荐强度	弱	利弊不确定或无论质量高低的证据均显示利弊相当